ADAM12 inhibitors and their use against inflammation-induced fibrosis
US10961536B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 29, 2017 |
| Grant date | Mar 30, 2021 |
| Priority date | — |
| Expiry date | Aug 29, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/382
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.